Stay updated on CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Sign up to get notified when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.

Latest updates to the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page
- Check6 days agoChange DetectedRevision updated from v3.3.1 to v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check13 days agoChange DetectedA new revision label v3.3.1 was added and the previous v3.2.0 label was removed.SummaryDifference0.0%

- Check20 days agoChange DetectedThe page's funding notice about government operations has been removed; the study details, eligibility criteria, and locations remain unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check34 days agoChange DetectedNo significant changes to core study information (design, eligibility criteria, endpoints, or results) are evident between the screenshots; the differences appear limited to minor UI/formatting updates. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check63 days agoChange DetectedCore content updated with a government funding notice and updated operating-status guidance; version updated from v3.1.0 to v3.2.0.SummaryDifference3%

- Check70 days agoChange DetectedUpdate the page to a new revision: from v3.0.2 to v3.1.0.SummaryDifference0.1%

Stay in the know with updates to CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CD40 Agonist APX005M + Nivolumab in Combo: Clinical Trial page.